Uveitic Macular Edema: Challenges and New Opportunities in Treatment

Author(s)/Faculty: Dilraj S. Grewal, MD, FASRS; Steven Yeh, MD, FASRS
Release Date: 6/23/2022Expiration Date: 6/22/2023
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.5
Content Type: LectureProvider:
Uveitic macular edema (UME) is the most common cause of vision loss in patients with uveitis, regardless of the anatomical type. The presence of UME has been shown to be associated with substantial clinical and economic burdens above those already present for uveitis patients without UME. Until recently, the management of UME has been challenging due to lack of guidance for treatment and FDA-approved therapies. Treatment has primarily utilized topical, intravitreal, or systemic corticosteroids, depending on etiology and severity, while in cases that did not respond, immunosuppressants, biologic therapies, and vitreoretinal surgery have been used. However, the FDA recently approved the first therapy for the treatment of UME which has provided evidence of good efficacy and safety. In this continuing medical education activity, experts in the field will review the etiologies of UME, and its burden on patients and health care resources, as well as evaluate the latest safety and efficacy of conventional, new, and emerging treatment options for the management of patients with UME.